Biotechnology

Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimm...

2025-08-25 08:00 1743

Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform

* The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression level...

2025-08-22 18:14 2485

Angel Yeast Cup Finals and Industry Development Conference Concludes

Engaging the World Through Fermented Flour-Based Foods SHANGHAI, Aug. 22, 2025 /PRNewswire/ -- The Finals of the 8th Angel Yeast Cup Chinese Fermented Dim Sum Contest and the 12th Fermented Flour-Based Food Industry Development Conference wrapped up in Ningxiang,Hunan province, a region widely r...

2025-08-22 18:04 2517

Biosyngen Unveils Innovative Strategies for Next-Generation TIL Therapies in Asia Bio 2025 Singapore

SINGAPORE, Aug. 22, 2025 /PRNewswire/ -- Asia Bio Innovation Summit 2025 is one of the premier industry-focused events inAsia and focus on the hottest topics of ADC and CGT. Asia Bio Innovation summit 2025 Singapore brought together 30+ world-class Speakers, 10+ Exhibitors and 200+ Attendees from...

2025-08-22 09:55 2852

BioDlink's Bevacizumab Approved for Market Launch in Indonesia, Marking Fourth Consecutive Emerging Market Authorization

* Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Control (BPOM), following Nigeria, Pakistan, and Colombia – accelerating global commercialization * Approval in ASEAN's largest pharma market strengthens BioDlink's position as a global supplier of ant...

2025-08-21 20:00 1527

SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health

* Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea. * Both reviews expanded cooperation, including next-generation preventive medicines. SEONGNAM, South Korea, Aug. 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biot...

2025-08-21 20:00 1710

Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results

Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled:  Eng...

2025-08-21 18:02 3108

SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM

Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solution...

2025-08-21 17:38 1633

GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal

YONGIN, South Korea, Aug. 21, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based inSouth Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The res...

2025-08-21 13:00 1395

Debut of new form of health supplement product! WCC biomedical collaborate with Synmosa toward the niche market!

TAIPEI, Aug. 21, 2025 /PRNewswire/ -- WCC Biomedical , a leader in novel drug delivery systems, will attend the upcomingNACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and laun...

2025-08-21 09:23 1554

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performan...

2025-08-21 08:23 2587

Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.

SHANGHAI, Aug. 20, 2025 /PRNewswire/ -- On August 11, 2025, the research team led by Professor Yuejun Chen, founder of UniXell Biotech, published an article titled "Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors" i...

2025-08-20 20:49 2223

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA

SHANGHAI, Aug. 19, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received INDclearance from the U.S. Food and Drug Administration (FDA). The clearance enables ...

2025-08-19 22:00 1682

WuXi Biologics Reports Solid 2025 Interim Results

* Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% * IFRS Gross profit margin expanded by 3.6% YoY to 42.7% * EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY * Adjusted EBITDA grew 20.6% YoY and adjusted net profit incr...

2025-08-19 20:35 2160

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monocl...

2025-08-19 20:09 1615

Nilesh Shah joins Illumina as Head of Region, AMEA

SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment ofNilesh Shah as Head of Region, AMEA, effective immediately. ...

2025-08-19 14:14 1868

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...

2025-08-19 13:26 1703

Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease

* Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] * In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisation...

2025-08-19 11:00 2424

RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary o...

2025-08-19 08:00 1870

Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).

* This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. * DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South...

2025-08-18 21:00 1731
1 ... 22232425262728 ... 341

Week's Top Stories